Tsalapaki Christina, Nikitopoulou Eleni, Boki Kyriaki A, Boumpas Dimitrios, Sfikakis Petros P, Vosvotekas Georgios, Voulgari Paraskevi V, Vassilopoulos Dimitrios
Joint Rheumatology Program, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
Clinical Immunology-Rheumatology Unit, 2 Department of Medicine and Laboratory, Hippokration General Hospital, Athens, Greece.
Mediterr J Rheumatol. 2018 Jun 29;29(2):103-105. doi: 10.31138/mjr.29.2.103. eCollection 2018 Jun.
Giant cell arteritis (GCA) is the most common systemic vasculitis in the aged population associated with significant morbidity due to the long term administration of corticosteroids and the presence of various comorbidities. Data regarding its current treatment modalities, comorbidities, morbidity and mortality in Greece are limited. In this multi-center, prospective study that begun at the end of 2015 patients with newly diagnosed GCA according to the modified 1990 ACR criteria, as well as individuals with established or relapsing disease have been included. During the 1 phase of the study that is still ongoing, data are being collected concerning demographic and clinical characteristics of the patients, treatment at the onset of the disease and at relapses, relapses, adverse events of therapy, comorbidities, hospitalizations and deaths. During the 2 and 3 phase of the study patients will be reevaluated 2 and 5 years after their 1st evaluation. The study is expected to provide valuable data regarding the current clinical characteristics, comorbidities, therapeutic regimens used, relapse rate, morbidity and mortality of patients with GCA.
巨细胞动脉炎(GCA)是老年人群中最常见的系统性血管炎,由于长期使用皮质类固醇以及存在各种合并症,其发病率较高。关于希腊目前对其治疗方式、合并症、发病率和死亡率的数据有限。在这项始于2015年末的多中心前瞻性研究中,纳入了根据1990年美国风湿病学会(ACR)修订标准新诊断的GCA患者,以及患有已确诊疾病或复发疾病的个体。在仍在进行的研究的第1阶段,正在收集有关患者的人口统计学和临床特征、疾病发作时及复发时的治疗、复发情况、治疗不良事件、合并症、住院情况和死亡情况的数据。在研究的第2和第3阶段,患者将在首次评估后的2年和5年进行重新评估。该研究预计将提供有关GCA患者当前临床特征、合并症、使用的治疗方案、复发率、发病率和死亡率的有价值数据。